Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05849129 | Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer(AIVAA) | recruiting | Phase 2 | 90 | The Canadian College of Naturopathic MedicineOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362940 | A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib | recruiting | Phase 1 / Phase 2 | 110 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 |
| NCT07354711 | A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3H Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07103395 | A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy | recruiting | Phase 2 | 41 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330050 | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330596 | QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC | recruiting | Phase 2 | 96 | Anhui Provincial Cancer HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05613413 | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)(LUNG-IST-127) | recruiting | Phase 2 | 36 | University of Illinois at ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04691817 | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | recruiting | Phase 1 / Phase 2 | 28 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07213375 | High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy(DEXTER) | recruiting | Phase 2 / Phase 3 | 80 | Rigshospitalet, DenmarkOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07323056 | Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer | recruiting | Phase 2 | 36 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06627738 | Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost(Cybertaxcis II) | recruiting | Phase 2 | 42 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07120698 | Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)(CTONG 2508) | recruiting | Phase 2 | 115 | Guangdong Association of Clinical TrialsOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06877299 | Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06295432 | A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | recruiting | Phase 2 | 90 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07073365 | Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)(BOOST) | recruiting | Phase 2 | 70 | Pusan National University HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07141264 | Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy | recruiting | Phase 2 | 32 | Tang-Du HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304739 | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07117890 | Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations(WU-KONG35) | recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06512051 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 248 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.(AcSé HER2) | recruiting | Phase 2 | 105 | UNICANCEROTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04966663 | Using ctDNA to Determine Therapies for Lung Cancer(ctDNA Lung RCT) | recruiting | Phase 2 | 66 | University Health Network, TorontoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05450965 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | recruiting | Phase 2 | 37 | University of Maryland, BaltimoreOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06102057 | PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC(PACCELIO) | recruiting | Phase 2 | 110 | TheraOpOTHER | 2 | Dec 17, 2025 | clinicaltrials |
| NCT06121505 | Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer | recruiting | Phase 2 | 114 | Sichuan UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07169552 | HC010 in First-line PD-L1 Positive Advanced NSCLC Patients | recruiting | Phase 2 | 50 | HC Biopharma Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07232849 | A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07224971 | Impact of Circadian Rhythm on Immunotherapy | recruiting | Phase 2 | 350 | Liza Villaruz, MDOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05886439 | LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06910761 | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06758700 | Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07264647 | Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 30 | Fondazione Ricerca TraslazionaleOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05751018 | Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07229729 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 300 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07206498 | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC(WAYWIN103) | recruiting | Phase 1 / Phase 2 | 48 | Wayshine Biopharm, Inc.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07058519 | A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC | recruiting | Phase 2 | 250 | Shanghai Chest HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2026source: clinicaltrials